Home › NDC Lookup › RxCUI directory › RxCUI 994530

Aspirin 385 MG / caffeine 30 MG / orphenadrine citrate 25 MG Oral Tablet [Norgesic] — RxCUI 994530

RxNorm drug concept · Semantic branded drug
RxCUI 994530 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI994530
Official nameAspirin 385 MG / caffeine 30 MG / orphenadrine citrate 25 MG Oral Tablet [Norgesic]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asNorgesic 25/385/30 (orphenadrine / aspirin / caffeine) Oral Tablet; Norgesic 25 MG / 385 MG / 30 MG Oral Tablet; ASA 385 MG / Caffeine 30 MG / Orphenadrine Citrate 25 MG Oral Tablet [Norgesic]
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Aspirin Rectal: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Great question. A rectal suppository gets the medication into your system through the lining of the rectum rather than your stomach. This can be helpful if you're having trouble sw...
  • Why would someone use a rectal suppository instead of just taking aspirin by mouth?
  • First, check that the foil or plastic packet is fully sealed and undamaged before you open it — don't use it if it looks like it's already been opened. Once you open it, insert the...
  • This is really important: aspirin — including the suppository form — should NOT be given to children or teenagers who have or are recovering from chicken pox or the flu. There is a...
📖 Read our full Aspirin Rectal guide →

🕸️ Concept Web — How Aspirin 385 MG / caffeine 30 MG / orphenadrine c... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Aspirin 385 MG / caffeine 30 MG / orphenadrine citrate 25 MG Oral Tablet [Norgesic] RxCUI 994530

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 5

    The active substance itself — no strength, form, or brand attached yet.

    • Aspirin 1191
    • Caffeine 1886
    • Orphenadrine 7715
    • Aspirin / caffeine / orphenadrine 466549
    • Orphenadrine citrate 7716
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Norgesic 218776
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Aspirin / caffeine / orphenadrine Oral Tablet 374758
    • Aspirin / caffeine / orphenadrine citrate Oral Tablet 2645484
    • Aspirin / caffeine / orphenadrine Oral Product 1153231
    • Aspirin / caffeine / orphenadrine Pill 1153232
    • Aspirin / caffeine / orphenadrine citrate Oral Product 2661484
    • Aspirin / caffeine / orphenadrine citrate Pill 2660979
    • Aspirin / caffeine / orphenadrine Oral Tablet [Norgesic] 367717
    • Aspirin / caffeine / orphenadrine citrate Oral Tablet [Norgesic] 2654521
    • +5 more in this family
  4. Clinical & branded drugs 5

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 19 of 24 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Aspirin 385 MG / caffeine 30 MG / orphenadrine citrate 25 MG Oral Tablet SCD · 994528
  • Aspirin 385 MG SCDC · 336010
  • Caffeine 30 MG SCDC · 315509
  • Orphenadrine citrate 25 MG SCDC · 994527
  • Aspirin / caffeine / orphenadrine Oral Tablet SCDF · 374758
  • Aspirin / caffeine / orphenadrine citrate Oral Tablet SCDFP · 2645484
  • Aspirin / caffeine / orphenadrine Oral Product SCDG · 1153231
  • Aspirin / caffeine / orphenadrine Pill SCDG · 1153232
  • Aspirin / caffeine / orphenadrine citrate Oral Product SCDGP · 2661484
  • Aspirin / caffeine / orphenadrine citrate Pill SCDGP · 2660979

Brand-Name Concepts

  • Aspirin 385 MG / caffeine 30 MG / orphenadrine citrate 25 MG [Norgesic] SBDC · 994529
  • Aspirin / caffeine / orphenadrine Oral Tablet [Norgesic] SBDF · 367717
  • Aspirin / caffeine / orphenadrine citrate Oral Tablet [Norgesic] SBDFP · 2654521
  • Norgesic Oral Product SBDG · 1185684
  • Norgesic Pill SBDG · 1185685
  • Norgesic BN · 218776

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 994530 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
61825-0305-60 60 TABLET in 1 BOTTLE, PLASTIC (61825-305-60) Norgesic Galt Pharmaceuticals, LLC 2022-05-16
Observed labelers: Galt Pharmaceuticals, LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.